If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the indication for Rezvoglar™ (insulin glargine-aglr)?
Rezvoglar is indicated to improve glycemic control in patients with diabetes.
Indication for Rezvoglar
Rezvoglar™ (insulin glargine-aglr) 100 units/mL is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes.1
Rezvoglar is not recommended for the treatment of diabetic ketoacidosis.1
Enclosed Prescribing Information
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: November 29, 2022